CERS vs. ANIK, OSUR, UTMD, ATRI, TCMD, LUNG, GUTS, NPCE, SGHT, and BVS
Should you be buying Cerus stock or one of its competitors? The main competitors of Cerus include Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Atrion (ATRI), Tactile Systems Technology (TCMD), Pulmonx (LUNG), Fractyl Health (GUTS), NeuroPace (NPCE), Sight Sciences (SGHT), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
Cerus received 268 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 72.26% of users gave Cerus an outperform vote while only 64.38% of users gave Anika Therapeutics an outperform vote.
Anika Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
In the previous week, Anika Therapeutics had 3 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Anika Therapeutics and 2 mentions for Cerus. Anika Therapeutics' average media sentiment score of 0.80 beat Cerus' score of -0.40 indicating that Cerus is being referred to more favorably in the news media.
91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 5.9% of Anika Therapeutics shares are held by insiders. Comparatively, 7.1% of Cerus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cerus has lower revenue, but higher earnings than Anika Therapeutics. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cerus has a net margin of -19.27% compared to Cerus' net margin of -45.39%. Cerus' return on equity of 0.48% beat Anika Therapeutics' return on equity.
Anika Therapeutics presently has a consensus target price of $29.50, indicating a potential upside of 16.14%. Cerus has a consensus target price of $3.83, indicating a potential upside of 94.59%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Anika Therapeutics.
Summary
Cerus beats Anika Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Cerus News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
